Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Lemoyneon Apr 14, 2021 4:23pm
175 Views
Post# 32994746

RE:RE:RE:RE:RE:Labs will become king

RE:RE:RE:RE:RE:Labs will become king People are funny.... Do you realize available numbers and trends puts LABS at less than 50 cents in 1 year?

Even if they managed 22% QoQ till next year (not guaranteed, remember that Q2/2020 rev increase surprise replenishing hope only for a disheartening Q3?).... without a drastic increase in gross margin, you'll have another 50-100M share dilution before summer 2022.

So unless you have a crystal ball showing you they will have 30-40%+ gross margins in a year, it's pure speculation to call/ believe in a gross margin improvement. No hard numbers showing any improvement. Mgmt expects it to happen as they expected the business to take off in second half of 2020 (read Q4 2019, Q1/Q2 2020 transcripts).

Investors are hoping the high cost inventory is all sold/ written off, but I ain't gonna believe that until I see hard numbers telling me gross margin is improving.
<< Previous
Bullboard Posts
Next >>